Loading...
XNAS
IMUX
Market cap148mUSD
Jul 09, Last price  
14.78USD
1D
0.07%
1Q
26.32%
Jan 2017
-99.15%
IPO
-99.69%
Name

Immunic Inc

Chart & Performance

D1W1MN
XNAS:IMUX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
66.96%
Rev. gr., 5y
%
Revenues
0k
Net income
-97m
L-3.32%
-5,879,000-6,701,000-32,718,000-47,667,000-52,023,000-40,969,000-52,078,000-41,475,000-34,826,000-44,017,000-92,945,000-120,407,000-93,612,000-100,507,000-97,172,000
CFO
-86m
L+1.23%
-7,831,000-9,244,000-28,648,000-40,825,000-49,952,000-35,774,000-40,397,000-43,165,000-28,545,000-46,124,000-83,233,000-65,144,000-70,828,000-84,766,000-85,806,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
URL
https://imux.com/
IPO date
Apr 17, 2014
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT